Antirheumatic Agents

• 

  Subject Areas on Research

  • "I would really want to know that they had my back": Transgender women's perceptions of HIV cure-related research in the United States. 
  • 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 
  • 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 
  • 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. 
  • 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. 
  • 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. 
  • 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. 
  • 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. 
  • 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. 
  • 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. 
  • 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. 
  • 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. 
  • 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. 
  • 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. 
  • 4th International Forum on Rheumatoid Arthritis: Great times near the Great Wall. 
  • A brief history of Wegener's granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by the Wegener's Granulomatosis Etanercept Trial Research Group. 
  • A landmark study on treatment strategies for rheumatoid arthritis. 
  • A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. 
  • A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. 
  • A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. 
  • A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. 
  • A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. 
  • ADA2 deficiency (DADA2) associated with Evans syndrome and a severe ADA2 genotype. 
  • Adipose depots, not disease-related factors, account for skeletal muscle insulin sensitivity in established and treated rheumatoid arthritis. 
  • Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges. 
  • Advances in the treatment of inflammatory arthritis. 
  • Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. 
  • Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. 
  • Antirheumatic medications in pregnancy and breastfeeding. 
  • Assessment and treatment of Down syndrome-associated arthritis: a survey of pediatric rheumatologists. 
  • Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography. 
  • Association of Traditional Chinese Medicine Use With Adherence to Prescribed Western Rheumatic Medications Among Chinese American Patients: A Cross-Sectional Survey. 
  • Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. 
  • Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). 
  • Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. 
  • Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. 
  • Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. 
  • Biomarkers in rheumatologic disease: a review. 
  • Biosimilars in rheumatology: understanding the rigor of their development. 
  • CD19: a promising B cell target for rheumatoid arthritis. 
  • Cardiac manifestations of Q fever infection: case series and a review of the literature. 
  • Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials. 
  • Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. 
  • Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. 
  • Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash. 
  • Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. 
  • Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. 
  • Choosing Wisely: the American College of Rheumatology's Top 5 for pediatric rheumatology. 
  • Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Clinical Features and Treatment of Down Syndrome Arthropathy: Experience from Two US Tertiary Hospitals. 
  • Clinical Trial Design in Juvenile Idiopathic Arthritis. 
  • Clinical benefits of intra-articular anakinra for arthrofibrosis. 
  • Clinical benefits of intra-articular anakinra for persistent knee effusion. 
  • Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. 
  • Clinical trials in pediatric rheumatology: comment on the editorial by Lehman. 
  • Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. 
  • Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. 
  • Clinician's comment on the management of pain in arthritis. 
  • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. 
  • Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis. 
  • Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy. 
  • Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. 
  • Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions. 
  • Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. 
  • Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. 
  • Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis. 
  • Controversies in the Management of Isolated Congenital Atrioventricular Block. 
  • Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. 
  • Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. 
  • Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis. 
  • Decreased expression of nicotinamide phosphoribosyltransferase in patients with juvenile idiopathic arthritis receiving methotrexate. 
  • Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. 
  • Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. 
  • Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study. 
  • Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE. 
  • Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions. 
  • Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. 
  • Dosing Variation at Initiation of Adalimumab and Etanercept and Clinical Outcomes in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study. 
  • Down Syndrome-Associated Arthritis Cohort in the New Childhood Arthritis and Rheumatology Research Alliance Registry: Clinical Characteristics, Treatment, and Outcomes. 
  • EULAR recommendations for disease management: guidance not guidelines. 
  • Early rheumatoid arthritis. 
  • Early-Onset Hydroxychloroquine Retinopathy and a Possible Relationship to Blood Levels: Comment on the Article by Petri et al. 
  • Editorial: Shifting the Goal Posts: Treatment Recommendations for Ankylosing Spondylitis and the Newly Defined Condition of Nonradiographic Axial Spondyloarthritis. 
  • Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. 
  • Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. 
  • Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. 
  • Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens. 
  • Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. 
  • Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. 
  • Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). 
  • Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). 
  • Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. 
  • Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014. 
  • Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. 
  • Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel. 
  • Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients. 
  • Family Planning Counseling for Women With Rheumatic Diseases. 
  • Fertility and infertility in rheumatoid arthritis. 
  • Fibroblastic rheumatism: a report of 4 cases with potential therapeutic implications. 
  • Folate depletion and increased glutamation in juvenile idiopathic arthritis patients treated with methotrexate. 
  • Formative research in clinical trial development: attitudes of patients with arthritis in enhancing prevention trials. 
  • Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. 
  • Good and bad memories following rituximab therapy. 
  • Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. 
  • Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. 
  • High and low molecular weight DNA cleavage in ovarian granulosa cells: characterization and protease modulation in intact cells and in cell-free nuclear autodigestion assays. 
  • High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. 
  • Hopefulness of 'Hope'. 
  • How Well Do Rheumatology Fellows Manage Acute Infusion Reactions? A Pilot Curricular Intervention. 
  • How do physicians weigh benefits and risks associated with treatments in patients with osteoarthritis in the United Kingdom? 
  • Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes. 
  • Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes. 
  • Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. 
  • Hydroxychloroquine in lupus pregnancy. 
  • Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. 
  • Hydroxychloroquine retinopathy: screening needed to prevent blindness. 
  • Hydroxychloroquine-induced hyperpigmentation: the staining pattern. 
  • Hydroxychloroquine: a treatable cause of cardiomyopathy. 
  • Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. 
  • IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. 
  • Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. 
  • Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. 
  • Improving the Safety of Teratogen Prescribing Practices in a Pediatric Rheumatology Clinic. 
  • Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. 
  • Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. 
  • Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment? 
  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. 
  • Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. 
  • Infliximab for the treatment of early rheumatoid arthritis. 
  • Infliximab in active early rheumatoid arthritis. 
  • Infliximab treatment for rheumatic disease: clinical and radiological efficacy. 
  • Infliximab treatment maintains employability in patients with early rheumatoid arthritis. 
  • Informed consent in a clinical trial of a novel treatment for rheumatoid arthritis. 
  • Interleukin 10 treatment for rheumatoid arthritis. 
  • Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis. 
  • Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. 
  • Juvenile idiopathic arthritis. 
  • Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. 
  • Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. 
  • Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. 
  • Managing contraception and pregnancy in the rheumatologic diseases. 
  • Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Metabolomic Profiling to Identify Molecular Biomarkers of Cellular Response to Methotrexate In Vitro. 
  • Methotrexate: new uses for an old drug. 
  • Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. 
  • Multisystem Inflammatory Syndrome in Children: Survey of Protocols for Early Hospital Evaluation and Management. 
  • Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. 
  • New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. 
  • New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA. 
  • New therapeutics in rheumatoid arthritis. 
  • New treatments for rheumatoid arthritis. 
  • Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project. 
  • Ocular findings in Japanese patients with hydroxychloroquine retinopathy developing within 3 years of treatment. 
  • Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. 
  • Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. 
  • PMTCT Adherence in Pregnant South African Women: The Role of Depression, Social Support, Stigma, and Structural Barriers to Care. 
  • Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. 
  • Patients' willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. 
  • Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. 
  • Perioperative management of rheumatoid medications. 
  • Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. 
  • Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren's syndrome. 
  • Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy. 
  • Pharmacogenomics in pediatric rheumatology. 
  • Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. 
  • Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases. 
  • Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial. 
  • Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. 
  • Power in numbers. 
  • Precision Medicine: Towards Individualized Dosing in Pediatric Rheumatology. 
  • Preconception Counseling. 
  • Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. 
  • Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis. 
  • Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. 
  • Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol. 
  • Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. 
  • Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma. 
  • Prescribing for Children With Rheumatic Disease: Perceived Treatment Approaches Between Pediatric and Adult Rheumatologists. 
  • Prescription patterns for children with juvenile idiopathic arthritis in Michigan Medicaid: a comparison by prescriber type. 
  • Progress in intra-articular therapy. 
  • Progress in the treatment of rheumatoid arthritis. 
  • Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. 
  • Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. 
  • Prologue: 2019 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). 
  • Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. 
  • Pulmonary complications of childhood rheumatic disease. 
  • Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. 
  • Radiographic progression in children with polyarticular juvenile rheumatoid arthritis: a pilot study. 
  • Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. 
  • Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. 
  • Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. 
  • Reply to Comment on: Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines. 
  • Reply to abnormalities on the multifocal electroretinogram may precede clinical signs of hydroxychloroquine retinotoxicity. 
  • Reply: To PMID 23218706. 
  • Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines. 
  • Reverse Translation in Advancing Pharmacotherapy in Pediatric Rheumatology: A Logical Approach in Rare Diseases with Limited Resources. 
  • Rheumatoid vasculitis: going, going, but not yet gone. 
  • Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement. 
  • Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. 
  • Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP). 
  • Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. 
  • Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. 
  • Safety updates in novel therapeutics for pediatric rheumatic disease. 
  • Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus. 
  • Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis. 
  • Self-Efficacy and Adherence Behaviors in Rheumatoid Arthritis Patients. 
  • Self-reported pain and disease symptoms persist in juvenile idiopathic arthritis despite treatment advances: an electronic diary study. 
  • Skeletal muscle disease in rheumatoid arthritis: the center of cardiometabolic comorbidities? 
  • Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177). 
  • Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. 
  • Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. 
  • Synovial fluid pro-inflammatory profile differs according to the characteristics of knee pain. 
  • Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. 
  • Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. 
  • Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. 
  • Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis. 
  • The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both. 
  • The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013. 
  • The direct and indirect costs of axial spondyloarthritis (axSpA) in Singapore. 
  • The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. 
  • The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. 
  • The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. 
  • The new FDA labeling rule: impact on prescribing rheumatological medications during pregnancy. 
  • The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. 
  • Therapeutic advancements in juvenile idiopathic arthritis. 
  • Therapy of rheumatoid arthritis: new developments and trends. 
  • Tides of inflammation: impact of biologics. 
  • Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. 
  • Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate. 
  • Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. 
  • Treatment failure in inflammatory arthritis: time to think about syndemics? 
  • Treatment of early rheumatoid arthritis. 
  • Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. 
  • Tuberculosis in the cytokine era: what rheumatologists need to know. 
  • Tumor necrosis factor blockers in rheumatoid arthritis. 
  • Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. 
  • Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. 
  • Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. 
  • Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. 
  • Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. 
  • Uveitis in children.